Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer (HyRec)

Multi-institutional Phase I/II Study: Neoadjuvant Chemoradiation With 5-FU (or Capecitabine) and Oxaliplatin Combined With Deep Regional Hyperthermia in Locally Advanced or Recurrent Rectal Cancer

This trial examines the feasibility, effectiveness and safety of a combination of radiotherapy (over a period of five weeks) and chemotherapy (with 5-FU or Capecitabine and Oxaliplatin) and 10 fractions of deep regional hyperthermia in patients with primary locally advanced or locally recurrent rectal cancer. Previous pelvic irradiation in case of a local recurrence is not excluded from the trial. The treatment protocol aims on a preoperatively improved tumor regression allowing less aggressive surgery in primary locally advanced rectal cancer and a higher rate of curative resections in heavily pretreated locally recurrent rectal cancers.

Primary endpoint of the trial is the feasibility rate of a multimodal regimen consisting of radiochemotherapy and hyperthermia. Secondary endpoints are local control, survival rates, and toxicity. It is planned to include a total number of 59 patients over a period of 2.5 years.

Study Overview

• Status: Recruiting
• Conditions: Rectal Cancer
• Intervention / Treatment: Radiation: Radiotherapy; Procedure: Hyperthermia; Drug: 5-Fluorouracil; Drug: Capecitabine; Drug: Oxaliplatin

• Study Type: Interventional
• Enrollment (Anticipated): 59
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Oliver Ott, MD; Phone Number: 33968 ++49(0)9131-85; Email: st-studiensekretatiat@uk-erlangen.de
• Study Contact Backup: Name: Sebastian Lettmaier, MD; Phone Number: 33968 ++49(0)9131-85; Email: st-studiensekretariat@uk-erlangen.de

Study Locations

• Germany
  • Bad Trissl, Germany, 83080
    • Recruiting
    • Klinik Bad Trissl, Innere Medizin
    • Principal Investigator: Bernhard Weber, MD
    • Sub-Investigator: Friedemann Peschke, MD
  • Duesseldorf, Germany, 40225
    • Recruiting
    • University Hospital
    • Sub-Investigator: Christiane Matuschek, MD
  • Erlangen, Germany, 91054
    • Recruiting
    • Universitätsklinikum Erlangen, Strahlenklinik
    • Sub-Investigator: Rainer Fietkau, MD
    • Principal Investigator: Oliver Ott, MD
  • München, Germany, 81377
    • Recruiting
    • LMU München, Campus Großhadern, Medizinische Klinik III, Hyperthermie
    • Principal Investigator: Rolf Issels, MD
    • Sub-Investigator: Katharina Lechner, MD
  • Oberstaufen, Germany, 87534
    • Recruiting
    • Schlossbergklinik
    • Principal Investigator: Thomas Licht, MD
    • Sub-Investigator: Blair Wolfgang, MD
  • Tübingen, Germany, 72076
    • Recruiting
    • Universitätsklinikum Tübingen, Radioonkologie
    • Principal Investigator: Daniel Zips, MD
    • Sub-Investigator: Johanna Gellermann, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age ≥ 18 years
• Histologically confirmed, locally advanced or recurrent (any recurrence of tumor within the lesser pelvis; resectable or non-resectable) adenocarcinoma of the rectum (UICC stage IIB-IV); distant oligo-metastases may be present.
• ECOG-performance status < 2
• Sufficient bone marrow function:
• WBC > 3,5 x 10^9/l
• Neutrophil granulocytes > 1,5 x 10^9/l
• Platelets > 100 x 10^9/l
• Hemoglobin > 10 g/dl
• Sufficient liver function: Bilirubin < 2,0 mg%, SGOT, SGPT, alkaline phosphatase, gGT less than 3 times upper limit of normal
• Serum creatinine < 1,5 mg%, glomerular filtration rate (or comparable test) > 50 ml/min
• Signed study-specific consent form prior to therapy
• Fertile patients must use effective contraception during and for 6 months after study treatment
• Considered fit for oxaliplatin and 5-FU-containing combination chemotherapy

Exclusion Criteria:

• Pelvic radiotherapy during the last 12 months
• Pregnant or lactating/nursing women
• Drug addiction
• On-treatment participation on other trials
• Active intractable or uncontrollable infection
• Prior or concurrent malignancy (≤ 5 years prior to enrolment in study) except rectal cancer or non-melanoma skin cancer or cervical carcinoma FIGO stage 0-1 if the patient is continuously disease-free
• Chronic diarrhea (> NCI CTC-Grad 1)
• Chronic inflammatory disease of the intestine
• Collagen vascular disease
• The presence of congenital diseases with increased radiation sensitivity, for example teleangiectatic ataxia, or similar
• Pre-existing uncontrolled cardiac disease, signs of cardiac failure, or rhythm disturbances requiring therapy
• Myocardial infarction within the past 12 months
• Congestive heart failure
• Complete bundle branch block
• New York Heart Association (NYHA) class III or IV heart disease
• Known allergic reactions on study medication
• Cardiac pacemaker
• Disease that would preclude chemoradiation or deep regional hyperthermia
• Any metal implants (with exception of non-clustered marker clips)
• Psychological, familial, sociological, or geographical condition that would preclude study compliance
• Patients deemed technically unsatisfactory for deep regional hyperthermia
• Cardiac symptoms (> NCI CTCAE Grade 1) due to pretreatment with fluoropyrimidines
• Neurological symptoms (> NCI CTCAE Grade 1) due to pretreatment with oxaliplatin
• Rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
• Oral anticoagulation

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: HyRec; Radiotherapy, Hyperthermia, 5-Fluorouracil (may be replaced by Capecitabine), Capecitabine (may be replaced by 5-Fluorouracil), Oxaliplatin

Radiation: Radiotherapy; 45 up to 50.4 Gy; daily dose 1,8 Gy, 5 days per weeks; Procedure: Hyperthermia; 10 sessions, therapeutic time 60 min; Drug: 5-Fluorouracil; 250 mg/m^2/d as continuous i.v. infusion on d1-14, 22-35 (may be preplaced by Capecitabine); Other Names: all brands of 5-Fluorouracil are allowed; Drug: Capecitabine; 1650 mg/m^2/d oral intake d1-14, 22-35 (may be replaced by 5-Fluorouracil); Other Names: all brands of Capecitabine are allowed; Drug: Oxaliplatin; 50 mg/m^2/d as 2-hour bolus infusion on d2, 9, 23, 30; Other Names: all brands of oxaliplatin are allowed

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Feasibility rate (i.e. rate of patients not experiencing dose-limiting toxicity [DLT])	Participants will be followed for the duration of therapy and for 6 weeks after the last study treatment dose (approximately 11 to 12 weeks)
Number of hyperthermia applications by patient	Duration of therapy (approximately 5 to 6 weeks)

Secondary Outcome Measures

Outcome Measure	Time Frame
Local progression-free survival	Participants will be followed for up to 5 years after the end of therapy (Follow up period)
Distant metastasis-free survival	Participants will be followed for up to 5 years after the end of therapy (Follow up period)
Overall survival	Participants will be followed for up to 5 years after the end of therapy (Follow up period)
Response rate	Participants will be followed for up to 5 years after the end of therapy (Follow up period)
Rate of R0-resections	Only of participants who are considered as resectable receive surgery in curative intention 4-6 weeks after completion of chemoradiation (results app. after 10 to 12 weeks after start of therapy)
Rate of acute and late toxicity	Participants will be followed for up to 5 years after the end of therapy (Follow up period)

Collaborators and Investigators

• Sponsor: University of Erlangen-Nürnberg Medical School
• Investigators: Principal Investigator: Oliver Ott, MD, Strahlenklinik, Universitätsklinikum Erlangen

Publications and helpful links

General Publications

• Ott OJ, Gani C, Lindner LH, Schmidt M, Lamprecht U, Abdel-Rahman S, Hinke A, Weissmann T, Hartmann A, Issels RD, Zips D, Belka C, Grutzmann R, Fietkau R. Neoadjuvant Chemoradiation Combined with Regional Hyperthermia in Locally Advanced or Recurrent Rectal Cancer. Cancers (Basel). 2021 Mar 13;13(6):1279. doi: 10.3390/cancers13061279.

Study record dates

Study Major Dates

• Study Start: September 1, 2012
• Primary Completion (Anticipated): June 1, 2022
• Study Completion (Anticipated): June 1, 2023

Study Registration Dates

• First Submitted: October 5, 2012
• First Submitted That Met QC Criteria: October 25, 2012
• First Posted (Estimate): October 30, 2012

Study Record Updates

• Last Update Posted (Actual): August 11, 2017
• Last Update Submitted That Met QC Criteria: August 9, 2017
• Last Verified: August 1, 2017

More Information

Terms related to this study

• Keywords: capecitabine; oxaliplatin; recurrent rectal cancer; rectal cancer; radiation; hyperthermia; chemoradiation; 5-FU
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Wounds and Injuries; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms; Body Temperature Changes; Heat Stress Disorders; Rectal Neoplasms; Hyperthermia; Fever; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Fluorouracil; Capecitabine; Oxaliplatin
• Other Study ID Numbers: ESHO201107/001